DRMA Stock Forecast: Dermata Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.51
−3.76% on the day

The median 12-month analyst price target for Dermata Therapeutics, Inc. is $2. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$2.7M
Ticker Nerd rank
26/ 100
Median analyst target
$2.00
Analysts covering
1
Revenue$0.0
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$2.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−17.6%
1M
−41.1%
YTD
−77.9%
1Y
−79.5%
From 52W high
−83.7%
From 52W low
0.0%
$0.51
$3.14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Dermata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
26/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
87
Volatility
37
Accruals
37
Momentum
32
Issuance
20
Growth
15
Value
12
Quality
8

Revisions (87): Analysts have, on balance, been raising their forecasts.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DRMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00$2.50$3.00$3.50Jan 26Apr 26Jul 26Oct 26DRMAHigh $2.00Median $2.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$2.00
Low
$2.00
Median
$2.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2025Maxim GroupMaintainsBuy$30 → $10
21 May 2025Maxim GroupMaintainsBuy—
21 Aug 2024Maxim GroupMaintainsBuy—
23 Mar 2023Maxim GroupMaintainsBuy—
21 Sept 2021Brookline CapitalInitiatesBuy$14
14 Sept 2021Maxim GroupInitiatesBuy$9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DRMA.

Market Radar

This page is one stock. Monday covers all of them.

DRMA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DRMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Dermata Therapeutics, Inc. returned −79.5% against +6.9% for the S&P 500, dividends included.

DRMA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26DRMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DRMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
35.9×

Cheaper than 5% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−241.5%

Higher than 6% of US stocks

Return on assets
−103.6%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dermata Therapeutics, Inc. has a market value of $2.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.1M.

  • Shares outstanding: 4.0M.

  • Dermata Therapeutics, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

DRMA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRMADermata Therapeutics, Inc.$2.7M26
GRIGRI Bio, Inc.$2.4M24
REVBRevelation Biosciences, Inc.$2.4M14
TRAWTraws Pharma, Inc.$2.7M56
ONCOOnconetix, Inc.$2.4M16
HCWBHCW Biologics Inc.$2.4M48
MBIOMustang Bio, Inc.$2.7M19

Take a look at DRMA’s peer groups, ranked by the model: consumer staples stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Dermata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about DRMA

What is the DRMA stock price forecast for 2026-2027?

The median 12-month analyst price target for Dermata Therapeutics, Inc. is $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRMA stock a buy right now?

Of the 1 analyst covering Dermata Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dermata Therapeutics, Inc. 26 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRMA?

As at 21 Nov 2026, Dermata Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).

Will DRMA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $2, and Ticker Nerd's factor model ranks Dermata Therapeutics, Inc. 26 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRMA stock forecast for 2030?

No analyst covering Dermata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $2 over the next 12 months.

How has DRMA stock performed over the past year?

Dermata Therapeutics, Inc. returned -79.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dermata Therapeutics, Inc. do?

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications.

Company

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications. Its product pipeline includes treatments designed for conditions such as acne, psoriasis, rosacea, and hyperhidrosis, as well as needle-free intradermal delivery approaches for aesthetic uses. Dermata Therapeutics also operates in the direct-to-consumer skincare market through the Tome brand, reflecting its broader emphasis on skin renewal and everyday dermatologic care. Headquartered in San Diego, California, Dermata Therapeutics serves as a specialized participant in the dermatology market, combining pharmaceutical development with consumer skincare products aimed at skin health and appearance.

CEO Mr. Gerald T. Proehl · 9 employees · United States · https://www.dermatarx.com